Vitalis Pharma is dedicated to enhancing patient care through innovative research and product development, particularly in the areas of multiple sclerosis, post-operative pain management, and dyslipidemia. The company is focused on reimagining existing treatments by leveraging its proprietary VTS-Aspirin platform. This platform aims to improve the therapeutic efficacy of aspirin, a well-established medication, by exploring its unique pharmacokinetic properties and developing formulations that allow for simultaneous ingestion with other drugs. This advancement could significantly improve patient compliance and treatment outcomes.

The VTS-Aspirin platform specifically targets the challenges associated with traditional aspirin use, such as the need for pre-treatment to mitigate side effects like the Niacin Flush. By creating a new formulation that enhances aspirin's pharmacokinetics and flush reduction capabilities, Vitalis Pharma seeks to streamline treatment regimens for patients. This innovative approach not only aims to improve the management of multiple sclerosis, post-operative pain, and dyslipidemia but also has the potential to benefit millions of patients by simplifying their medication routines and enhancing overall therapeutic effectiveness.

United States

Vitalis is a pre-clinical stage pharmaceutical company that is dedicated to changing the treatment of multiple sclerosis, post-op pain (non-opioid), and dyslipidemia through innovative therapies. Vitalis hopes to address major side effects of some of these treatments, such as flush, while also improving outcomes.

Vitalis Pharma

Company Details